The American journal of medicine
-
Randomized Controlled Trial Clinical Trial
The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia.
To evaluate the efficacy of lovastatin in African Americans (AA) diagnosed with primary hypercholesterolemia. ⋯ The HMG-CoA (3-hydroxyl-3 methylglutary coenzyme A) reductase inhibitor lovastatin in a dose of 20 mg per day was effective in decreasing TC, LDL, and TG levels in an AA population. Considering that the AA population is at substantially increased risk for hypertension and cardiovascular morbidity, more aggressive and wider use of HMG-CoA reductase inhibitors should be employed in reducing elevated plasma cholesterol levels.